Main > > >INFECTIOUS DISEASES.

---

Acinetobacter Bacteria Infections. TREAT.: Minocycline for
Injection.
(*) Company : Melinta Therapeutics.
TradeMark: Minocin.
Web-Site : www.minociniv.com/.
UpDate: 2018. 01.21.




Acute Bacterial Skin and Skin Structure Infections (ABSSSI).
TREAT.: Delafloxacin.
Antimicrobial Susceptibility Tests>
Hardy Diagnostics s Delafloxacin Antimicrobial Susceptibility Disk (HardyDiskTM), Liofilchem® Delafloxacin MIC Test Strip (MTS), and Thermo Scientific™ Sensititre™ MIC System. USA>Approved.
USA Approval Date: 2017. 06.19.
USA Launch Date: 2017. 10.30.
(*) Company : Melinta Therapeutics Inc.
TradeMark: Baxdela.
Web-Site : www.baxdela.com.
UpDate: 2018. 01.21.




Acute Bacterial Skin and Skin Structure Infections (ABSSSI).
TREAT.: OmadaCycline. (AminoMethylCycli-
ne.
USA Approval Date: 2018. 10.02.
(*) Company : Paratek Pharmaceuticals.
TradeMark: Nuzyra
UpDate: 2018. 10.03.




Acute Bacterial Skin and Skin Structure Infections (ABSSSI).
TREAT.: OritaVancin.
caused or suspected to be caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible [MSSA] and -resistant [MRSA] isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus, and Enterococcus faecalis (vancomycin-susceptible isolates only).
EU Approval Date: 2015. 03.30.
USA Approval Date: 2014. 08.06.
(*) Company; Patents; TradeMark & Web-Site Available on
Request.
UpDate: 2018. 01.21.




AIDS. Anorexia (loss of appetite), Cachexia (severe malnutrition), or an unexplained, significant Weight Loss.
TREAT.: Megestrol Acetate Oral Suspension. Generics.
USA Approval Date: 2017. 12.04.
(*) Company Available on Request
UpDate: 2017. 12.05.




AIDS. TREAT.: Atazanavir Capsules. Generic.
Protease Inhibitor.
TREAT. of HIV-1 infection for patients 6 years and older weighing at least 15 kg.
USA Exclusive Launch Date: 2017. 12.27.
(*) Company: Teva Pharmaceutical Industries Ltd.
UpDate: 2017. 12.28.




AIDS. TREAT.: Bictegravir 50mg+Emtricitabine 200mg+Tenofovir Alafenamide 25mg
CA Approval Date: 2018. 07.12.
USA Approval Date: 2018. 02.07.
(*) Company : Gilead Sciences.
TradeMark: Biktarvy
UpDate: 2018. 07.13.




AIDS. TREAT.: Darunavir 800 mg+Cobicis-
tat 150 mg+Emtricitabine 200 mg+Teno
fovir Alafenamide 10 mg Single Tablet
Regimen.
Approved in CA; EU & USA.
(*) Company : Janssen.
TradeMark: Symtuza.
UpDate: 2018. 07.18.




AIDS. TREAT.: Dolutegravir 50 mg+Emtricitabine 200mg+
Tenofovir Alafenamide 25 mg Tablets. GENERIC.
USA Tentative Approval Date: 2018. 02.20.
(*) Company: Mylan NV.
UpDate: 2018. 02.21.




AIDS. TREAT.: Efavirenz Tablets USP, 600 mg. GENERIC.
USA Launch Date: 2018. 02.01.
(*) Company: Mylan NV. www.mylan.com/
UpDate: 2018. 02.02.




AIDS. TREAT.: Efavirenz+Lamivudine+
+Tenofovir Disoproxil Fumarate (TDF)
IN Launch Date : 2017. 08.08.
USA Approval Date: 2018. 03.28.
(*) Company : Mylan.
TradeMark: Avonza (IN)
TradeMark: Symfi (USA)
UpDate: 2018. 03.29.




AIDS. TREAT.: IbalizuMAb.
USA Approval Date: 2018. 03.06.
(*) Company : TaiMed Biologics Inc.
TradeMark: Trogarzo
Web-Site : www.taimedbiologics.com/pipeline/33
UpDate: 2018. 03.07.




AIDS. TREAT.: Tenofovir Disoproxil Fumarate Tablets 300 mg
Generic.
USA Launch Date: 2017. 12.15.
(*) Company Available on Request.
UpDate: 2017. 12.16.




Antibiotic Resistant CPOs (Carbapenemase-Producing Organisms). DIAG.: next-generation molecular screening test
EU Approval Date: 2018. 01.15.
(*) Companies; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 01.16.




Antibiotics>Telavancin.HCl for Inj.
USA Approval Date: 2009. 09.13.>CSSSI
USA Approval Date: 2013. 06.21.>HABP/
>VABP
USA Approval Date: 2016. 05.09.>HABP/
>VABP Associated Bacteremia.
(*) Companies; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2018. 11.12.




Bacillus Anthracis Infection Diagnostics
Announcement Date: 2018. 12.10.
(*) Company; Patent & PR Web-Site Avai-
lable on Request.
UpDate: 2018. 12.14.




Bacterial Infectious DISs.>Diag.>Identi-
fication (ID.) & Antibiotic Susceptibi lity Testing (AST) System Platform.
. ID. Testing via Fluorescent In Situ
Hybridization (FISH)
. AST determined by Morphokinetic Cellu-
lar Analysis (“MCA”)
(Live-Cell Optical Analysis)
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 02.24.




Borrelia burgdorferi IgG/IgM (Lyme Di-
sease). Diagnostics.
(*) Company; Patents & Web-Site Avai-
lable on Request.
UpDate: 2018. 08.27.




Borrelia burgdorferi IgG/IgM (Lyme Di-
sease). Diagnostics. ELISA Assay.
USA Clearance Date: 2018. 06.13.
(*) Company : Gold Standard Diagnostics.
Web-Site: gsdx.us/assays/lyme/
UpDate: 2018. 06.14.




Borrelia burgdorferi IgG/IgM (Lyme Di-
sease). Diagnostics. Fluorescent Immunoassay (FIA).
USA Approval Date: 2017. 10.23.
(*) Company : Quidel Corp.
TradeMark: Sofia
Web-Site :
www.quidel.com/immunoassays/rapid-
lyme-tests/sofia-lyme-fia
UpDate: 2018. 08.27.




Candidiasis>Cutaneous Candidiasis (Fungus)>TREAT.:
Nystatin+Triamcinolone Acetonide Generic Cream.
USA Approval Date: 2017. 08.16.
USA Launch Date: 2017. 11.27.
(*) Company Available on Request.
UpDate: 2017. 11.28.




Chagas Disease. TREAT.: BenznidAzole.
USA Approval Date: 2017. 08.29.
(*) Company: Insud Pharma. www.insudpharma.com/
UpDate: 2018. 02.25.




Clostridium difficile Associated Diarrhea. TREAT.:
Vancomycin.HCL for Oral Solution.
USA Approval Date: 2018. 01.29.
USA Launch Date: 2018. 04.02.
(*) Company : CutisPharma Inc.
cutispharma.com.
TradeMark: FIRVANQ
Web-Site : www.firvanq.com/
UpDate: 2018. 04.03.




Clostridium Difficile Infection (Bacteria)>DIAG.:
POC (Point Of Care) Instrument
EU Approval Date: 2017. 01.11.
USA Approval Date: 2017. 11.28.
(*) Company & TradeMark Available on
Request.
UpDate: 2017. 11.29.




Complicated Intra Abdominal Infections (CIAI). TREAT.:
Ceftazidime+AviBactam.
DE Launch Date: 2017. 03.14.
EU Approval Date: 2016. 06.28.
UK Launch Date: 2017. 03.14.
USA Approval Date: 2015. 02.25.
USA Label UpDate: 2017. 01.30.
(*) Companies; Patents; TradeMarks & Web-Site Available on
Request.
UpDate: 2018. 02.03.




Complicated Urinary Tract Infections (CUTI) Including Pyelo-
Nephritis. TREAT.: Ceftazidime+AviBactam.
DE Launch Date: 2017. 03.14.
EU Approval Date: 2016. 06.28.
UK Launch Date: 2017. 03.14.
USA Approval Date: 2015. 02.25.
USA Label UpDate: 2017. 01.30.
(*) Companies; Patents; TradeMarks & Web-Site Available
on Request.
UpDate: 2018. 02.03.




Complicated Urinary Tract Infections (CUTI) Including Pyelo-
Nephritis. TREAT.: Meropenem+Vaborbactam for Inj.
USA Approval Date: 2017. 08.30.
(*) Company; TradeMark & Web-Site Available on Request.
UpDate: 2018. 01.21.




Coughs Control and to Break up Mucus, making coughs more productive.
Guaifenesin+Dextromethorphan.HCl ER Tab. OTC GENERIC.
USA Final FDA Approval and Planned Launch: 2018. 03.07.
(*) Company: Perrigo.
UpDate: 2018. 03.08.




Covid-19 (CoronaVirus). Treat.: Cough
Simulation Device.
EU>CE Mark: Yes.
(*) Company; JPost Article; Patent;
TradeMark & Web-Site Available on
Request.
UpDate: 2020. 02.17.




CytoMegaloVirus Infection. Prevention In Adult Allogeneic HSCT: Letermovir.
USA Approval Date: 2017. 11.09.
(*) Company; Patent; TradeMark & Web-Site Available on
Request.
UpDate: 2018. 02.01.




Diagnostics. qPCR System. Ultra Portable
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 04.12.




Fascioliasis. (Liver Fluke Infestation).
Treat.: Triclabendazole.
USA Approval Date: 2019. 02.13.
(*) Company : Novartis.
Patent : Expired
TradeMark: Egaten
UpDate: 2019. 02.15.




Group A Streptococcus Infection. DIAG.: Point-of-Care Sofia® 2 Instrument for Use with Sofia Strep A+ Assay.
Company: Quidel Corp. (www.quidel.com)
USA>FDA Clearance and CLIA Waiver Date: 2017. 12.21.
UpDate: 2017. 12.23.




Hepatitis B Virus Infection. PREVENTION. Vaccine.
USA Approval Date: 2017. 11.09.
USA Launch Date: 2018. 01.08.
(*) Company; Patents & TradeMark Available on Request.
UpDate: 2018. 01.09.




Hepatitis B Virus Infection. TREAT.:
Entecavir Tablets. GENERIC.
USA Final Approval Date: 2018. 03.27.
(*) Company: Breckenridge Pharma. Inc.
www.bpirx.com
UpDate: 2018. 03.28.




Hepatitis C Virus Infection. DIAG.:
Xpert HCV VL Fingerstick.
EU Approval Date: 2018. 09.19.
(*) Company: Cepheid.
UpDate: 2018. 09.20.




Hepatitis C Virus Infection. TREAT.: Glecaprevir+Pibrentas
vir. [for Adults across all major GenoTypes (GT1-6)].
Glecaprevir: Protease Inhibitor.
CA Approval Date: 2017. 08.17.
EU Approval Date: 2017. 07.28.
JP Approval Date: 2017. 09.27.
JP Launch Date: 2017. 11.30.
USA Approval Date: 2017. 08.03.
(*) Company; Patent>Assignee & Trade-
Mark Available on Request.
UpDate: 2017. 12.01.




Hepatitis C Virus Infection. TREAT.:
Ravidasvir+Danoprevir Oral
CN Approval Date: 2020. 07.31.
(*) Company; Patent & TradeMarks Avai-
lable on Request.
UpDate: 2021. 03.29.




Hepatitis C Virus Infection. TREAT.:
Sofosbuvir+Velpatasvir Tablets.
CA Approval Date : ?
CN Approval Date : ?
JP Approval Date : 2019. 01.08.
USA Approval Date: ?
(*) Company : Gilead
TradeMark: Epclusa
Web-Site : www.epclusa.com
UpDate: 2019. 01.08.




Identification every known pathogen (bacteria, virus, fungi
or parasite) in a single test.
Uses software & DNA sequencing.
(*) Company : Aperiomics Inc.
Web-Site : aperiomics.com
UpDate: 2018. 03.13.




Influenza (Flu) Virus Infection. DIAG.:
Xpert® Xpress Flu Test.
Flu Results in as Little as 20 Minutes.
USA FDA Clearance and CLIA Waiver Date: 2018. 01.09.
(*) Company: Cepheid. www.cepheid.com.
UpDate: 2018. 01.10.




Influenza (Flu) Virus Infection. DIAG.:
Molecular Flu A/Flu B Test.
Point of Care Testing System.
EU Approval Date : 2018. 01.24.
USA Approval Date: 2018. 02.07.
(*) Company : Mesa Biotech Inc. www.mesabiotech.com
TradeMark: Accula.
UpDate: 2018. 02.08.




Influenza (Flu) Virus Infection. DIAG.:
Molecular Flu A/Flu B Test.
Point of Care Testing System.
USA Launch Date: 2018. 03.13.
(*) Company : Sekisui Diagnostics.
www.sekisuidiagnostics.com
Developed By: Mesa Biotech Inc. www.mesabiotech.com
TradeMark : Silaris.
UpDate: 2018. 03.14.




Influenza (Flu) Virus Infection. Prevention.
Cell-Based QuadriValent Vaccine. Four Years of Age and
Older.
USA Approval Date: 2016. 05.23.
(*) Company & TradeMark Available on
Request.
UpDate: 2017. 12.03.




Influenza (Flu) Virus Infection. Prevention.
Egg-Based QuadriValent Vaccine. Five Years of Age and
Older.
USA Approval Date: 2017. 09.14.
(*) Company & TradeMark Available on
Request.
UpDate: 2017. 12.03.




Influenza (Flu) Virus Infection. TREAT.:
Baloxavir Marboxil Tablets 10 mg/20 mg.
Target: Endonuclease Region.
JP Approval Date : 2018. 02.23.
USA Approval Date: 2018. 10.24.
(*) Companies; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.25.




Influenza (Flu) Virus Infection. TREAT.: Oseltamivir Phosphate for Oral Suspension. GENERIC.
USA Launch Date: 2018. 03.01.
(*) Company: Amneal Pharmaceuticals.
UpDate: 2018. 03.02.




Influenza (Flu) Virus Infection. TREAT.:
Zanamivir for Inhalation. Brand.
(*) Company : GSK.
Patent Expiration Date: 2012. 11.10.
TradeMark : Relenza.
UpDate: 2018. 04.29.




Legionella Bacteria Infection. DIAG.
(*) Company : Albagaia Ltd.
Web-Site: hydrosense-legionella.com
UpDate: 2018. 07.31.




Malaria. Prevention: Tafenoquine Succi nate.
AU Approval Date: 2018. 09.
AU Launch Date: 2019. 03.20.
(*) Companies; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.21.




Measles, Mumps, Rubella, and Varicella (MMRV). DIAG. Tests.
Introduction Date: 2018. 08.21.
(*) Company : True Health
Web-Site : truehealthdiag.com
UpDate: 2018. 08.22.




Mycobacterium Avium Complex (MAC) Lung Disease. Treat.: Amikacin Liposome
Inhalation Suspension.
USA Approval Date: 2018. 09.28.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.25.




Mycoplasma Genitalium. DIAG.:
Aptima® Mycoplasma genitalium assay
USA Approval Date: 2019. 01.23.
(*) Company: Hologic.
UpDate: 2019. 01.24.




Neisseria Gonorrhoeae. DIAG.: Multiplex qPCR Test.
EU Approval Date: 2018. 12.06.
(*) Company : SpeeDx Pty. Ltd
TradeMark: ResistancePlus® GC
Web-Site :
plexpcr.com/resistanceplus-gc/
UpDate: 2018. 12.07.




Pneumonia. Community Acquired Bacterial
Pneumonia. TREAT.: OmadaCycline. (Ami-
noMethylCycline).
USA Approval Date: 2018. 10.02.
(*) Company : Paratek Pharmaceuticals
TradeMark: Nuzyra.
UpDate: 2018. 10.03.




Pneumonia. Hospital Acquired Bacterial Pneumonia. TREAT.: Ceftazidime+ AviBactam.
USA Approval Date: 2018. 02.01.
(*) Companies; Patents; TradeMarks &
Web-Site Available on Request.
UpDate: 2018. 02.03.




Pneumonia. Ventilator Acquired Bacterial Pneumonia. TREAT.:
Ceftazidime+AviBactam.
USA Approval Date: 2018. 02.01.
(*) Companies; Patents; TradeMarks & Web-Site Available
on Request.
UpDate: 2018. 02.03.




Rabies Virus Infection. PostExposure Prophylaxis:
Rabies Immune Globulin [Human]) 300 IU/mL.
USA Approval Date: 2018. 02.06.
(*) Company : Grifols. www.grifols.com/en.
TradeMark: HyperRAB.
UpDate: 2018. 02.07.




Respiratory Syncytial Virus (RSV) Infec-
tion Prevention in Infants: PalivizuMAb.
(*) Company : Swedish Orphan Biovitrum
AB. (USA Rights)
Patent : Expired
TradeMark: Synagis
UpDate: 2018. 11.14.




River Blindness. (Onchocerciasis). TREAT
.: Moxidectin 8 mg Oral.
USA Approval Date: 2018. 06.13.
(*) Company:Medicines Development Ltd.
www.medicinesdevelopment.com
UpDate: 2018. 07.30.




Sepsis. Bacterial Sepsis. Diag.:
EU Approval Date : 2017. 07.18
USA Approval Date: 2018. 05.29.
(*) Company : T2 Biosystems Inc.
TradeMark: T2Bacteria
UpDate: 2018. 07.11.




Sepsis. Blood Culture Collection Device with "Skin Contaminant Diversion" Technology. FALSE Positives!
USA FDA 510(k) Cleared.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2017. 11.29.




Staphylococcus Aureus EnteroColitis. TREAT.: Vancomycin.HCl
for Oral Solution.
USA Approval Date: 2018. 01.29.
USA Launch Date: 2018. 04.02.
(*) Company : CutisPharma Inc.
cutispharma.com
TradeMark: FIRVANQ
Web-Site : www.firvanq.com/
UpDate: 2018. 04.03.




Tuberculosis Infection. DIAG.:
EU Approval Date: 2018. 07.25.
(*) Company : Co-Diagnostics Inc.
TradeMark: Logix Smart™ MTB Test
UpDate: 2018. 07.26.




Tuberculosis Infection. DIAG.:
JP Approval Date: 2018. 02.08.
(*) Company : Qiagen NV.
TradeMark: QuantiFERON®-TB Gold Plus
UpDate: 2018. 02.10.




Urinary Tract Infections. Treat.:
Nitrofurantoin Capsules. Generic.
CA Launch Date: 2018. 05.14.
(*) Company: Pharmascience Inc.
www.pharmascience.com
UpDate: 2018. 05.15.




Virus Infectious Diseases. Technology
Platform.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 04.26.




Virus Infectious Diseases. TREAT.:
ExtraCorporeal Affinity HemoDialysis
Device.
(*) Company; Patents; TradeMark & Web-
Site Available on Request
UpDate: 2018. 07.26.




Zika Virus Infection. DIAG.
EU CE Mark Date: 2018. 10.18.
(*) Company; Patent; TradeMarks & Web-
Site Available on Request.
UpDate: 2018. 10.19.


>INFECTIOUS DISEASES.'s products
This section has no products